Fatality rates in candida infections are between 30 and 40 percent. Until the advent of lipid-based products, conventional amphotericin B was generally considered to be the treatment of choice to combat these infections. However, its propensity to cause kidney toxicity has severely limited its dosage, a result that many believe limits its efficacy. Marketing applications have been filed and are being reviewed in a number of other countries. The Liposome Company is a broad-based biopharmaceutical company developing and marketing products based on its knowledge of lipids and liposomes.
Research programs are underway in cancer, inflammation and gene therapy delivery.
Any question regarding a medical diagnosis, treatment, referral, drug availability or pricing should be directed to either a licensed physician or to the product's manufacturer.